CO2019013649A2 - Composiciones farmacéuticas sólidas orales de dabigatrán etexilato - Google Patents

Composiciones farmacéuticas sólidas orales de dabigatrán etexilato

Info

Publication number
CO2019013649A2
CO2019013649A2 CONC2019/0013649A CO2019013649A CO2019013649A2 CO 2019013649 A2 CO2019013649 A2 CO 2019013649A2 CO 2019013649 A CO2019013649 A CO 2019013649A CO 2019013649 A2 CO2019013649 A2 CO 2019013649A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
solid pharmaceutical
oral solid
dabigatran etexilate
etexilate
Prior art date
Application number
CONC2019/0013649A
Other languages
English (en)
Spanish (es)
Inventor
Ali Türkyilmaz
Arzu Palantöken
Ezel Uraz
Yildiz Gülkok
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64559741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019013649(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/TR2018/050221 external-priority patent/WO2019004980A2/en
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of CO2019013649A2 publication Critical patent/CO2019013649A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2019/0013649A 2017-05-10 2019-12-03 Composiciones farmacéuticas sólidas orales de dabigatrán etexilato CO2019013649A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2017/06848A TR201706848A2 (tr) 2017-05-10 2017-05-10 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR2018/06309A TR201806309A2 (tr) 2017-05-10 2018-05-04 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
PCT/TR2018/050221 WO2019004980A2 (en) 2017-05-10 2018-05-10 SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE

Publications (1)

Publication Number Publication Date
CO2019013649A2 true CO2019013649A2 (es) 2020-05-15

Family

ID=64559741

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013649A CO2019013649A2 (es) 2017-05-10 2019-12-03 Composiciones farmacéuticas sólidas orales de dabigatrán etexilato

Country Status (8)

Country Link
EP (2) EP3634388A2 (ru)
AU (1) AU2018293361B2 (ru)
BR (1) BR112019023781A2 (ru)
CO (1) CO2019013649A2 (ru)
EA (1) EA201992644A1 (ru)
NZ (1) NZ759901A (ru)
TR (2) TR201706848A2 (ru)
WO (1) WO2019004979A2 (ru)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
ES2631980T3 (es) 2010-07-01 2017-09-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
JP6215239B2 (ja) * 2012-02-21 2017-10-18 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ダビガトランエテキシラートの経口医薬組成物
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
WO2015155297A1 (en) * 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
IN2015CH01145A (ru) * 2015-03-09 2016-09-16
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor

Also Published As

Publication number Publication date
EA201992644A1 (ru) 2020-04-07
TR201806309A2 (tr) 2018-11-21
AU2018293361A1 (en) 2020-01-02
WO2019004979A3 (en) 2019-04-11
NZ759901A (en) 2021-12-24
TR201706848A2 (tr) 2018-11-21
BR112019023781A2 (pt) 2020-06-02
EP3621599A2 (en) 2020-03-18
EP3634388A2 (en) 2020-04-15
WO2019004979A2 (en) 2019-01-03
AU2018293361B2 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
CR20160538A (es) Combinación
JO3302B1 (ar) باي بيريديل -ايثيل -بيرامدين مستبدل كمثبط جريلين o-أسيل ترانسفيريز
DK3634468T3 (da) Fast sammensætning til oral indgivelse
TR201906325T4 (tr) Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri.
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2017013073A (es) Inhibidores de grelina o-aciltransferasa.
MA44720A (fr) Comprimés à désintégration orale
IN2014MN02245A (ru)
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
WO2019004980A3 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
CO2019013649A2 (es) Composiciones farmacéuticas sólidas orales de dabigatrán etexilato
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
AR107163A1 (es) Inhibidores de quinasa
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
EA201991288A1 (ru) Фармацевтические композиции на основе дабигатрана